Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This compound is a cephalosporin-related small molecule, identified in chemical databases as a derivative of the cephem nucleus (5-thia-1-azabicyclo[4.2.0]octane). It features an acetyloxymethyl group at the 3-position and a complex 7-position side chain containing a glycylamino-heptanoic acid moiety. Structurally similar to cephalosporin antibiotics, it is designed to interact with penicillin-binding proteins (PBPs), which are critical enzymes in bacterial peptidoglycan synthesis. By binding to these proteins, the molecule inhibits the cross-linking of the bacterial cell wall, leading to cell lysis. It is primarily documented as a research compound or ligand (e.g., PDB ligand G2A) used in crystallographic studies to map the active sites of enzymes like beta-lactamases or PBPs. No evidence exists for its development as a therapeutic agent or its use in clinical trials.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on (6S)-N-[(2S,3R,6R,7R)-3-(Acetyloxymethyl)-2-carboxy-8-oxo-5-thia-1-azabicyclo[4.2.0]octan-7-yl]-6-[(2-aminoacetyl)amino]-7-hydroxy-7-oxoheptanimidate.